ACOBIOM is a French biotechnology company specialised in the discovery and evaluation of RNA/DNA Biomarkers, and in the development of innovative diagnostics focused on precision medicine applications. These expertise and activity enable the company to provide multi-omics services, as well as new in-vitro tests associated with treatments. Its scientific team has 26 years' experience in molecular biology and bioinformatics engineering which is the support to produce and deliver premium molecular biological data, thanks to a powerful technology platform integrating NGS sequencing platforms, qPCR instruments and a Data Science division including a machine learning know-how. The team aims to overcome technological barriers, in order to bring added value to scientists or clinicians, for applications in diagnostics and drug development: identifying biomarkers and therapeutic targets, exploring metabolic pathways, analysing the effects of treatments, selecting patients, predicting patient responses to therapies. ACOBIOM is also involved in the development of predictive tests based on RNA biomarkers, especially in oncology. Thus, the company has established expertise and proprietary tools based on NGS systems that enable it to meet health authorities’ guidelines in an accurate and effective manner.